Please assess the completion status of the following clinical trial:

Trial Title: The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary immune thrombocytopenia (ITP) confirmed by excluding other supervened causes of thrombocytopenia;~* Platelet count of less than 30×109/L at enrolment~* Patients who did not achieve a sustained response to treatment with full-dose corticosteroids for a minimum duration of 4 weeks or who relapsed during steroid-tapering or after its discontinuation.~* 18 years older.~Exclusion Criteria:~* Secondary immune thrombocytopenia (e.g., patients with HIV, HCV, Helicobacter pylori infection or patients with systemic lupus erythematosus)~* congestive heart failure~* severe arrhythmia~* nursing or pregnant women~* aspartate aminotransferase and alanine transaminase levels ≥ 3× the upper limit of the normal threshold criteria~* creatinine or serum bilirubin levels each 1•5 times or more than the normal range~* active or previous malignancy~* Unable to do blood routine test for the sake of time, distance, economic issues or other reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All-trans retinoic acid ＆Danazol (Type: EXPERIMENTAL): Danazol 400mg po and ATRA 10mg bid po
- Danazol (Type: ACTIVE_COMPARATOR): Danazol 400mg po

Based on this trial design, predict the completion outcome and termination type (if applicable).